New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations

Basit Öğe Kaydı
dc.authoridDegim, Zelihagul/0000-0003-2596-3615
dc.authorid, ahmet/0000-0001-6274-5700
dc.authoridYilmaz, Sukran/0000-0002-7945-1124
dc.authoridMutlu-Agardan, N. Basaran/0000-0002-4882-3124
dc.contributor.authorMutlu, N. Basaran
dc.contributor.authorDegim, Zelihagul
dc.contributor.authorYilmaz, Sukran
dc.contributor.authorEssiz, Dinc
dc.contributor.authorNacar, Ahmet
dc.date.accessioned2024-09-18T20:55:50Z
dc.date.available2024-09-18T20:55:50Z
dc.date.issued2011
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractThe aim of this study was to determine the transportations of rivastigmine containing from various liposome formulations through Madin Darby Canine Kidney (MDCK) cells monolayer and to compare the in vitro test results with in vivo. There is no other liposome formulation of rivastigmine and the transportations of rivastigmine through MDCK cell monolayers or related study available in the literature. Cytotoxicity (MTT) test was used to determine cell viabilities. The effect of sodium-taurocholate or dimethyl-beta-cyclodextrine as penetration enhancer was also investigated. Characterization and stability studies for liposome formulations were performed. Permeation experiments of rivastigmine were performed through MDCK cells and dialysis membrane. The kinetic of release from liposomes was also investigated. The highest apparent permeability coefficient (log. values) was obtained with sodium-taurocholate liposomes for --1.15 +/-+/- 0.16 for MDCK cell. Rivastigmine liposomes and solutions were also administered to mice orally and intraperitonally. Acetylcholinesterase (AChE) activity was determined by Ellman method. AChE% inhibition values were calculated for both blood and brain after administration of rivastigmine solution and liposomes. The highest AChE inhibition was observed for rivastigmine-sodium-taurocholate liposomes. Histological observations of the mice'' brains were performed under transmission electron microscope (TEM). The histological results were also indicated and supported all these findings.en_US
dc.description.sponsorshipGazi University [02/2006-17]en_US
dc.description.sponsorshipThis study was supported by a research grant from Gazi University (02/2006-17). The authors declare here that there is no conflict of interest with anybody or any organizations.en_US
dc.identifier.doi10.3109/03639045.2010.541262
dc.identifier.endpage789en_US
dc.identifier.issn0363-9045
dc.identifier.issn1520-5762
dc.identifier.issue7en_US
dc.identifier.pmid21231901en_US
dc.identifier.scopus2-s2.0-79958761285en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage775en_US
dc.identifier.urihttps://doi.org/10.3109/03639045.2010.541262
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12069
dc.identifier.volume37en_US
dc.identifier.wosWOS:000291445300004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofDrug Development and Industrial Pharmacyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRivastigmineen_US
dc.subjectliposomeen_US
dc.subjectMDCKen_US
dc.subjectalzheimer diseaseen_US
dc.titleNew perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulationsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
2.69 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu